Evidence map›Paper›PMID 39776299›Full record

ArticlePhysiological reports2024

Hypertension and obesity independently drive hypertrophy and alter mitochondrial metabolism in a mouse model of heart failure with preserved ejection fraction.

Benjamin Werbner, Sophie L Stephens, Deborah Stuart, Travis M Hotchkiss, Jonathan Chapman, Katsuhiko Funai, Nirupama Ramkumar, Sihem Boudina

Abstract read
In one paragraph

Article in Physiological reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Immunometabolism in heart failure.Nature reviews. Cardiology · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Benjamin WerbnerDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah, USA.
Sophie L StephensDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah, USA.
Deborah StuartDivision of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Travis M HotchkissDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah, USA.
Jonathan ChapmanDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah, USA.
Katsuhiko FunaiDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah, USA.
Nirupama RamkumarDivision of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Sihem BoudinaDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0002-4711-1109

Funding

PE methylation in skeletal muscle energy efficiencyR01DK107397 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI FUNAI, KATSUHIKO · 2017 to 2025
$3.8M
The Role of PRDM16 in Cardiac Development and CardiomyopathyR01HL149870 · NHLBI · UNIVERSITY OF UTAH · PI BOUDINA, SIHEM · 2020 to 2023
$2.8M
University of Utah Interdisciplinary Training Program in Computational Approaches to Diabetes and Metabolism ResearchT32DK110966 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Karen Louise Eilbeck, Marcus Guy Pezzolesi · 2016 to 2026
$2.6M
Pathobiological mechanisms of cardiac disease in PGM1-CDGR01HL167866 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sihem Boudina, Kent Lai · 2024 to 2026
$1.9M
Lands cycle and skeletal muscle insulin actionR01DK127979 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI FUNAI, KATSUHIKO · 2022 to 2025
$1.9M
Soluble (pro)renin receptor regulation of kidney fibrosisR01DK133271 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI NIRUPAMA RAMKUMAR · 2023 to 2026
$1.8M
MSRP in Metabolism, Diabetes, Digestive and Kidney DiseasesT35DK103596 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI BEDDHU, SRINIVASAN, ROUND, JUNE LOUISE · 2015 to 2025
$758k
HHS | NIH | NHLBI | NHLBI Division of Intramural Research (DIR) R01HL149870-01A1HHS | NIH | NHLBI | NHLBI Division of Intramural Research (DIR) R01HL167866HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM) 2T32DK110966-06HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM) T35DK103596NHLBI NIH HHS R01 HL149870NHLBI NIH HHS R01 HL167866NIDDK NIH HHS R01 DK107397NIDDK NIH HHS R01 DK127979NIDDK NIH HHS R01 DK133271NIDDK NIH HHS T32 DK110966NIDDK NIH HHS T35 DK103596
6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) has recently emerged as an insidiously and increasingly prevalent heart failure phenotype. HFpEF often occurs in the context of hypertension and obesity and presents with diastolic dysfunction, ventricular hypertrophy, and myocardial fibrosis. Despite growing study of HFpEF, the causal links between early metabolic changes, bioenergetic perturbations, and cardiac structural remodeling remain unclear. This study sought to elucidate the contribution of the respective pathophysiological drivers of the HFpEF symptom suite using a recently developed two-hit mouse model. By studying the independent and concomitant consequences of hypertension and obesity-driven metabolic dysfunction on cardiac structure and function, we revealed the causative drivers of cardiac functional, structural, and metabolic remodeling in male HFpEF mice. We found that hypertensive male mice developed diastolic dysfunction and cardiac hypertrophy regardless of obesity status and that obese mice exhibited altered systemic glucose metabolism and increased cardiac mitochondrial fatty-acid metabolism independent of hypertension status. Taken together, our results suggest that the cardiac structural and metabolic HFpEF symptoms in this two-hit model occur as direct results of each of the two "hits." The results of this study help to clarify the pathogenic HFpEF cascade, providing causal insights that may aid in the development of more precisely targeted therapeutics.

Indexed as

Heart FailureHypertensionMice, Inbred C57BLMitochondria, HeartObesityStroke VolumeAnimalsCardiomegalyDisease Models, AnimalMaleMicecardiac hypertrophychronic hypertensionfatty‐acid oxidationHFpEFobesity

Identifiers

PMID39776299
PMCPMC11427896

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.